Drug Overview

WNT-5A mimic hexapeptide Foxy-5 (also known as Foxy-5) is an investigational, N-formylated, six-amino acid peptide that mimics the biological activity of the WNT-5A protein. Unlike many cancer drugs that target primary tumor growth, Foxy-5 is a first-in-class anti-metastatic agent. It is specifically designed to restore the tumor-suppressing signaling of WNT-5A, which is often lost or downregulated in several types of solid tumors.

In the clinical landscape of March 2026, Foxy-5 is recognized for its unique approach to treating cancer by preventing the spread (metastasis) of tumor cells. By activating the non-canonical Wnt signaling pathway, Foxy-5 aims to “stabilize” tumor cells, making them less likely to break away from the primary tumor and colonize other parts of the body. This makes it a primary candidate for patients with cancers that are characterized by a loss of WNT-5A, such as breast, colon, and prostate cancer.

Generic Name: WNT-5A mimic hexapeptide Foxy-5.
Code Name: Foxy-5.
Drug Class: Wnt Signaling Mimic; Anti-metastatic Agent.
Mechanism: Mimics the activity of WNT-5A to activate non-canonical Wnt signaling and inhibit cell migration and invasion.
Route of Administration: Intravenous (IV) infusion.
FDA Approval Status: Investigational. As of March 2026, Foxy-5 is not FDA-approved. It is currently being evaluated in Phase 2 clinical trials (such as the NeoFox trial) for its efficacy in preventing the spread of colon cancer.

What Is It and How Does It Work? (Mechanism of Action)

The Wnt signaling pathway is a complex network of proteins that regulates cell growth, movement, and differentiation. Foxy-5 targets a specific branch of this pathway.

1. The Role of WNT-5A

WNT-5A is a “non-canonical” Wnt protein that typically acts as a tumor suppressor by regulating cell adhesion and inhibiting cell movement.

Loss of Signaling: In many aggressive cancers, the expression of WNT-5A is significantly reduced. This loss allows cancer cells to become more “mobile” and invasive, facilitating their spread to distant organs.
Restoring the Signal: Foxy-5 is a small peptide that binds to the same receptors as the full WNT-5A protein. By “mimicking” the protein, it restores the missing signals that keep cells in place.

2. Molecular Level Mechanisms

Receptor Binding: Foxy-5 binds to Frizzled receptors (specifically Frizzled-2 and Frizzled-5) on the surface of the tumor cell.
Activating the “Brakes”: This binding activates the non-canonical Wnt/Ca2+ pathway.
Inhibiting Migration: The activation increases cell-to-cell adhesion and reduces the activity of proteins that allow cells to crawl (such as those involved in the epithelial-mesenchymal transition or EMT).
Preventing Invasion: As a result, the tumor cells become less invasive and lose their ability to enter the bloodstream or lymphatic system.

FDA Approved Clinical Indications

There are currently no FDA-approved indications for Foxy-5.

Clinical research through 2026 has primarily focused on:

Early-Stage Colon Cancer: Investigated as a “neoadjuvant” therapy (given before surgery) to reduce the risk of the cancer spreading during or after the surgical removal of the primary tumor.
WNT-5A Low Breast Cancer: Studied in patients whose tumors show a deficiency in WNT-5A protein, where the risk of metastasis is particularly high.
Prostate Cancer: Early-phase trials have explored its role in preventing the progression of localized disease to metastatic bone disease.

Dosage and Administration Protocols

As an investigational drug, Foxy-5 dosing is strictly determined by clinical trial protocols (such as the NeoFox study).

Treatment Parameter	Clinical Specification (2025–2026)
Route	Intravenous (IV) bolus injection.
Dosing Schedule	Typically administered 3 times per week.
Duration of Treatment	In neoadjuvant settings, it is given for several weeks prior to the scheduled surgery.
Dose Escalation	Studied at various levels to determine the optimal biological dose (OBD) rather than the maximum tolerated dose, since it is very well-tolerated.

Clinical Efficacy and Research Results

As of early 2026, results from the Phase 2 NeoFox trial have provided significant insights into the drug’s potential:

Safety as a Benchmark: Foxy-5 has consistently shown an excellent safety profile. Because it mimics a natural signaling protein and does not directly kill cells (like chemotherapy), it lacks the toxic “off-target” effects typically seen in oncology.
Metastatic Delay: Preliminary data from 2025 suggested that patients with WNT-5A low colon cancer who received Foxy-5 had a measurable reduction in the number of “circulating tumor cells” (CTCs) in their blood.
Surgical Window Therapy: The concept of using Foxy-5 as a “bridge” to protect patients during the critical window before surgery is a major focus of ongoing research.

Safety Profile and Side Effects

Foxy-5 is remarkably well-tolerated, which is a major advantage for its use as a preventive therapy.

Common Side Effects (>10%):

Infusion Site Reactions: Minor redness or discomfort at the site of the IV injection.
Fatigue: Mild systemic tiredness reported by some patients.
Nausea: Generally low-grade and manageable without medication.

Serious Risks:

Theoretical Risks: Because Foxy-5 affects cell signaling, researchers monitor for any potential changes in normal cell growth or wound healing, although no significant serious adverse events (SAEs) have been consistently linked to the drug in early trials.
Immunogenicity: As with any peptide-based therapy, there is a small potential for the body to develop antibodies against the drug, though this has not significantly impacted efficacy in current studies.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, Foxy-5 is being used to study “Cancer Stem Cell Quiescence.” Researchers are investigating whether restoring Wnt-5a signaling can force “migratory” cancer stem cells back into a dormant state. In 2026, there is also intense focus on “Organ-Specific Tropism.” Scientists are exploring if Foxy-5 can specifically prevent the colonization of the liver and lungs—the most common sites for colon cancer metastasis. Furthermore, studies are looking into whether Foxy-5 can improve the “integrity” of the blood-tumor barrier to prevent cell escape.

Patient Management and Practical Recommendations

Pre-treatment Requirements:

WNT-5A Testing: Many trials require a biopsy sample to confirm that the tumor has low levels of WNT-5A protein to ensure the drug is targeted at those most likely to benefit.
Baseline Imaging: CT or MRI scans to establish the starting state of the primary tumor and confirm no pre-existing distant metastasis.

“Do’s and Don’ts” List:

DO keep your three-times-weekly infusion appointments; because Foxy-5 is a short-acting peptide, consistent dosing is required to maintain its “stabilizing” effect.
DO report any unusual bruising or persistent tiredness to your clinical trial coordinator.
DON’T expect the drug to “shrink” your tumor in the way that chemotherapy does; its goal is to act as a biological shield against the spread of the disease.
DON’T miss your scheduled surgery date, as Foxy-5 is designed to work with the surgical intervention, not replace it.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Foxy-5 is an investigational agent and is not approved by the U.S. FDA for any indication. Access is limited exclusively to registered clinical trials. Always consult with a qualified oncologist regarding your specific diagnosis and eligibility for research participation.